Genomic profiling of this patient suggests that AITL arose from a founder clone harboring DNMT3A and TET2 mutations; the addition of the IDH2 mutation was presumably associated with progression to AITL. Here, DNMT3A is linked to angioimmunoblastic T-cell lymphoma.